Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. - Wikidata - awgldk - TriplyDB

Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.

Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.

http://www.wikidata.org/entity/Q36482542

about

Molecular pathology of lung cancer: key to personalized medicine.First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance.Identifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer model Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.Apoptosis Gene Expression Profile in Early-Stage non Small Cell Lung Cancer

P2860

Q27691299-7A090ABD-CBC8-4175-9FF3-C6286AD98C1C Q33401434-10629F37-2CBA-4310-9E01-5031269C1520 Q33605906-A1E01AA9-79D9-466D-B240-A1C1EED8A99C Q34092023-0244833A-1FC8-4D6E-82C8-00E3BD1DD25B Q35540678-656A40EB-B8B2-4DC1-83BC-CEEA43D44C19 Q36084854-82870DF8-2207-49EF-8770-16DA0000422E Q36206242-64B158FC-C26F-40F5-BFCE-BEC8D02EA873 Q36402044-F2850AE2-D590-4000-B16C-9D0F06DBBC59 Q45933675-740E2DC1-CDD6-4F6A-B4A7-26320D02A513 Q47151967-0D902CCE-39D0-4D23-BC3C-76B02219A3B1 Q58050577-7C1CA209-A53A-4452-8E90-072E9BBE1468

P2860

Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.

http://www.wikidata.org/entity/Q36482542

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Epidermal growth factor recept ...... of non-small cell lung cancer.

@ast

Epidermal growth factor recept ...... of non-small cell lung cancer.

@en

type

label

Epidermal growth factor recept ...... of non-small cell lung cancer.

@ast

Epidermal growth factor recept ...... of non-small cell lung cancer.

@en

prefLabel

Epidermal growth factor recept ...... of non-small cell lung cancer.

@ast

Epidermal growth factor recept ...... of non-small cell lung cancer.

@en

P1433

Q36482542-BE2F64AB-D4F9-45B7-B907-BC045F56019D

P1476

Q36482542-E9065AC1-910F-40A2-AF05-5B081ADD6920

P2093

Q36482542-F50979FE-2FFE-4192-AF4F-879F2CCE98D1

Q36482542-FA503082-E609-4889-83FB-CA5749F92DB8

P2860

Q36482542-019AE565-4646-4D54-82A1-CC4FAED49FD9

Q36482542-01D0AFED-111F-4004-8B00-E9E052ED9FAD

Q36482542-028DCB59-AAE1-47C7-8D32-9D3CA9705791

Q36482542-034BDBC8-BA77-4728-A482-2F3880008AC9

Q36482542-03C1E8E6-E2B3-4649-B6F2-87C4C54499D9

Q36482542-041DF9CD-CF64-474E-91A2-FD498F324463

Q36482542-08992B23-8836-454D-BC0D-BE70558E0D1F

Q36482542-0CBA76C3-B225-43DE-A396-70FA93C9196A

Q36482542-0D09C26E-4132-4D2C-A18A-9EC4929A5677

Q36482542-0D257C26-1464-4854-B99B-0FFB1FFFA52E

P304

Q36482542-8B4A7135-6258-4BD9-8018-296DB59ECD49

P31

Q36482542-E1B20551-C4CE-44DB-B007-553494E444A0

P356

Q36482542-77C91181-86FF-4783-8846-261B6B914567

P407

Q36482542-68DA710D-2E4A-4FA0-8785-40C54F7ECC7B

P433

Q36482542-450BE8AB-B90C-4811-B120-73F9F3C50B47

P478

Q36482542-D86AA04E-46A6-484D-A53C-82D0A0912D3E

P577

Q36482542-9FC285B5-A57B-41EB-800C-DC3B1C3FFE3C

P698

Q36482542-6512BCBF-6CAF-478B-BE9C-218C14F0C15E

P932

Q36482542-B1FCB5CF-BB2D-4AF0-B608-B422B263FEB8

P356

1078-0432.CCR-09-0520

P1433

Clinical Cancer Research

P1476

Epidermal growth factor recept ...... of non-small cell lung cancer.

@en

P2093

Alan Sandler

http://www.w3.org/2001/XMLSchema#string

Leora Horn

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Cancer statistics, 2008

Tumor angiogenesis: therapeutic implications

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

5040-5048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-0520

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19671872

http://www.w3.org/2001/XMLSchema#string

P932

3528182

http://www.w3.org/2001/XMLSchema#string